Human CellExp IL-28A, Human recombinant protein
Human Cellexp Human Recombinant IL-28A
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8IZJ0 |
---|---|
Calculated MW | 24 kDa, monomer, non-glycosylated |
Gene ID | 282616 |
---|---|
Gene Symbol | IFNL2 |
Other Names | Interleukin-28A, IL-28A, IFN-Lambda 2, Interferon-Lambda 2, Cytokine ZCYTO20, IL28A, IFNL2, ZCYTO20. |
Gene Source | Human |
Source | Human 293 cell expressed |
Assay&Purity | SDS-PAGE; > 95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Results | 0.5 to 5 ng/ml |
Application Notes | Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin. |
Format | Lyophilized |
Storage | -80°C; Lyophilized in PBS. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IL-28A is distantly related to type I interferons and the IL-10 family. Expression of IL-28A is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha. IL-28A exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumor activity. They act similarly to IFNs, but are less effective generally and have activity in a more limited range of cell lines. IL-28A induces ELR (-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. It is able to generate tolerogenic DCs, an activity that could thwart IFN-beta functions. IL-28A produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection.
References
Sheppard P.,et al.Nat. Immunol. 4:63-68(2003).
Zhu H.,et al.Virol. J. 2:80-80(2005).
Kotenko S.V.,et al.Nat. Immunol. 4:69-77(2003).
Li M.C.,et al.Acta Pharmacol. Sin. 27:453-459(2006).
Donnelly R.P.,et al.J. Interferon Cytokine Res. 30:555-564(2010).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.